{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:08:21Z","timestamp":1792786101824,"version":"4.5.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["K23AR073334"],"award-info":[{"award-number":["K23AR073334"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["R03AR078938"],"award-info":[{"award-number":["R03AR078938"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001311","name":"RRF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001311","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol-Myers Squibb and Principia"},{"name":"Zenas Biopharma"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>IgG4-related disease (IgG4-RD) can affect nearly any organ and is often treated with glucocorticoids, which contribute to organ damage and toxicity. Comorbidities and healthcare utilization in IgG4-RD are poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cohort study using claims data from a US managed care organization. Incident IgG4-RD cases were identified using a validated algorithm; general population comparators were matched by age, sex, race\/ethnicity and index date. The frequency of 21 expert-defined clinical outcomes associated with IgG4-RD or its treatment and healthcare-associated visits and costs were assessed 12\u2009months before and 36\u2009months after the index date (date of earliest IgG4-RD-related claim).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 524 cases and 5240 comparators. Most cases received glucocorticoids prior to (64.0%) and after (85.1%) the index date. Nearly all outcomes, many being common glucocorticoid toxicities, occurred more frequently in cases vs comparators. During follow-up, the largest differences between cases and comparators were seen for gastroesophageal reflux disease (prevalence difference: +31.2%, P\u2009&amp;lt;\u20090.001), infections (+17.3%, P\u2009&amp;lt;\u20090.001), hypertension (+15.5%, P\u2009&amp;lt;\u20090.01) and diabetes mellitus (+15.0%, P\u2009&amp;lt;\u20090.001). The difference in malignancy increased during follow-up from +8.8% to +12.5% (P\u2009&amp;lt;\u20090.001). Some 17.4% of cases used pancreatic enzyme replacement therapy during follow-up. Over follow-up, cases were more often hospitalized (57.3% vs 17.2%, P\u2009&amp;lt;\u20090.01) and\/or had an emergency room visit (72.0% vs 36.7%, P\u2009&amp;lt;\u20090.01); all costs were greater in cases than comparators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with IgG4-RD are disproportionately affected by adverse outcomes, some of which may be preventable or modifiable with vigilant clinician monitoring. Glucocorticoid-sparing treatments may improve these outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae230","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:27:54Z","timestamp":1713486474000},"page":"2457-2466","source":"Crossref","is-referenced-by-count":11,"title":["The clinical outcomes and healthcare resource utilization in IgG4-related disease: a claims-based analysis of commercially insured adults in the United States"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4708-7038","authenticated-orcid":false,"given":"Zachary S","family":"Wallace","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital , Boston, MA, USA"},{"name":"Harvard Medical School , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandarvaka","family":"Miles","sequence":"additional","affiliation":[{"name":"Sanofi , Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Smolkina","sequence":"additional","affiliation":[{"name":"Sanofi , Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Petruski-Ivleva","sequence":"additional","affiliation":[{"name":"Sanofi , Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duane","family":"Madziva","sequence":"additional","affiliation":[{"name":"Sanofi , Mississauga, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishan","family":"Guzzo","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Cook","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Fu","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital , Boston, MA, USA"},{"name":"Harvard Medical School , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6588-9435","authenticated-orcid":false,"given":"John H","family":"Stone","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital , Boston, MA, USA"},{"name":"Harvard Medical School , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon K","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital , Boston, MA, USA"},{"name":"Harvard Medical School , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"key":"2024090322080355500_keae230-B1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41584-020-0500-7","article-title":"IgG4-related disease: an update on pathophysiology and implications for clinical care","volume":"16","author":"Perugino","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2024090322080355500_keae230-B2","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/14397595.2016.1259602","article-title":"A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease","volume":"27","author":"Masaki","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2024090322080355500_keae230-B3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/rheumatology\/key227","article-title":"Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial","volume":"58","author":"Yunyun","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2024090322080355500_keae230-B4","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.semarthrit.2020.01.010","article-title":"Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: a randomized clinical trial","volume":"50","author":"Wang","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2024090322080355500_keae230-B5","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/art.39132","article-title":"International consensus guidance statement on the management and treatment of IgG4-related disease","volume":"67","author":"Khosroshahi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024090322080355500_keae230-B6","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/ard-2023-223950","article-title":"Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults","volume":"82","author":"Wallace","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024090322080355500_keae230-B7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","article-title":"Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis","volume":"76","author":"Miloslavsky","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024090322080355500_keae230-B8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/acr2.11405","article-title":"Derivation and Validation of Algorithms to Identify Patients With Immunoglobulin-G4-Related Disease Using Administrative Claims Data","volume":"4","author":"Wallace","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2024090322080355500_keae230-B9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","article-title":"Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records","volume":"148","author":"Kiyota","year":"2004","journal-title":"American heart journal"},{"key":"2024090322080355500_keae230-B10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"2024090322080355500_keae230-B11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCOUTCOMES.113.000743","article-title":"Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with medicare claims","volume":"7","author":"Kumamaru","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2024090322080355500_keae230-B12","author":"Elixhauser","year":"2017"},{"key":"2024090322080355500_keae230-B13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"Journal of chronic diseases"},{"key":"2024090322080355500_keae230-B14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-publhealth-040617-013517","article-title":"Modeling Health Care Expenditures and Use","volume":"39","author":"Deb","year":"2018","journal-title":"Annu Rev Public Health"},{"key":"2024090322080355500_keae230-B15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","article-title":"The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease","volume":"79","author":"Wallace","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024090322080355500_keae230-B16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2016-312049","article-title":"Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis","volume":"66","author":"Masamune","year":"2017","journal-title":"Gut"},{"key":"2024090322080355500_keae230-B17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s00535-019-01615-4","article-title":"Insulin secretion improvement during steroid therapy for autoimmune pancreatitis according to the onset of diabetes mellitus","volume":"55","author":"Noguchi","year":"2020","journal-title":"J Gastroenterol"},{"key":"2024090322080355500_keae230-B18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S2468-1253(16)30106-6","article-title":"Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer","volume":"1","author":"Hart","year":"2016","journal-title":"The lancet Gastroenterology & hepatology"},{"key":"2024090322080355500_keae230-B19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1507\/endocrj.EJ14-0078","article-title":"Analysis of pancreatic endocrine function in patients with IgG4-related diseases, in whom autoimmune pancreatitis was ruled out by diagnostic imaging","volume":"61","author":"Ito","year":"2014","journal-title":"Endocr J"},{"key":"2024090322080355500_keae230-B20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrneph.2015.95","article-title":"IgG4-related disease and the kidney","volume":"11","author":"Cortazar","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"2024090322080355500_keae230-B21","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/art.39773","article-title":"Association of IgG4-Related Disease With History of Malignancy","volume":"68","author":"Wallace","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024090322080355500_keae230-B22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"key":"2024090322080355500_keae230-B23","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/jgh.15809","article-title":"Nationwide epidemiological survey of immunoglobulin G4-related disease with malignancy in Japan","volume":"37","author":"Sumimoto","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"2024090322080355500_keae230-B24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13075-021-02652-2","article-title":"The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis","volume":"24","author":"Yu","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2024090322080355500_keae230-B25","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1093\/rheumatology\/keab172","article-title":"The Association of Smoking with IgG4-Related Disease: a Case-Control Study","volume":"60","author":"Wallwork","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024090322080355500_keae230-B26","doi-asserted-by":"crossref","first-page":"100385","DOI":"10.1016\/j.jhepr.2021.100385","article-title":"Blue-collar work is a risk factor for developing IgG4-related disease of the biliary tract and pancreas","volume":"3","author":"Hubers","year":"2021","journal-title":"JHEP Rep"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae230\/58167521\/keae230.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2457\/59007417\/keae230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2457\/59007417\/keae230.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T06:46:09Z","timestamp":1725432369000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/9\/2457\/7651349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,4,19]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae230","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,4,19]]}}}